RxDoctor Payments Data

Leslie Hinds, NP

Nurse Practitioner · Denver, CONPI 1649310244

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,799 of the $8,520 with a category attached, or 79.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 9.6% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,520in general payments, 2019–2025

Across 333 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$815
  • Novartis$747
  • Seagen Inc.$566
  • AstraZeneca$487
  • Pfizer$443
  • Daiichi Sankyo Inc.$367
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$6,79980%
  • Education$1,22314%
  • Other$4996%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)27$815
Novartis18$747
Seagen Inc.14$566
AstraZeneca(2 entities)24$487
Pfizer25$443
Daiichi Sankyo Inc.19$367
Gilead14$325
Merck15$311
AVEO Pharmaceuticals, Inc.6$310
Bristol Myers Squibb13$303
E.r. Squibb & Sons, L.L.C.13$292
Sanofi10$288
Pharmacyclics LLC, An Abbvie Company8$269
Genentech USA, Inc.14$266
GSK10$226
Lilly USA, LLC5$215
Karyopharm Therapeutics Inc.8$212
EMD Serono, Inc.6$174
Beigene USA, Inc.2$142
Exelixis Inc.5$113
Tersera Therapeutics LLC5$109
Amgen5$107
Genmab U.S., Inc.4$103
Regeneron Healthcare Solutions, Inc.4$95
Astellas Pharma US Inc3$78
Sobi, Inc3$69
Telix Pharmaceuticals2$68
Eisai Inc.3$65
Pharmacosmos Therapeutics Inc.3$62
Ipsen Biopharmaceuticals, Inc3$60
Alnylam Pharmaceuticals Inc.2$52
Recordati_rare_diseases_inc.2$47
Taiho Oncology, Inc.3$46
Boston Scientific1$44
Coherus Oncology, Inc.2$44
Immunocore Limited2$39
Sun Pharmaceutical Industries Inc.2$37
Stemline Therapeutics Inc.2$36
Incyte Corporation2$34
Blueprint Medicines Corporation1$33
Pharmaessentia USA Corporation2$31
Boehringer Ingelheim2$31
Morphosys, US Inc.2$31
Takeda Pharmaceuticals U.S.A., Inc.1$29
Novocure Inc.1$28
Dendreon Pharmaceuticals LLC1$24
AbbVie1$23
Array Biopharma Inc1$23
Deciphera Pharmaceuticals Inc.1$22
Epizyme, Inc.1$20
G1 Therapeutics, Inc.1$19
Servier Pharmaceuticals LLC1$18
Dova Pharmaceuticals1$18
Organon1$17
Rigel Pharmaceuticals, Inc.1$16
ADC Therapeutics America, Inc.1$16
Myovant Sciences Inc.1$16
Medtronic1$14
Beone Medicines USA, Inc.1$14
Myriad Genetic Laboratories, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,520 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado

Medicare billing

Part B allowed, 2024
$14,659
Medicare patients
140
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide46$887,662
Lenalidomide26$382,529
KisqaliRibociclib Succinate15$236,802
GilotrifAfatinib Dimaleate11$123,449
ImbruvicaIbrutinib13$117,664
EliquisApixaban46$56,878
XareltoRivaroxaban23$22,548
Anastrozole56$886
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine14$524
Oxycodone Hcl30$492
Letrozole21$445
Dexamethasone22$257
Potassium Chloride12$243
Levothyroxine Sodium12$137
Acyclovir11$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$303$887,66246 claims
NovartisKisqali$747$236,80215 claims
Boehringer IngelheimGilotrif$31$123,44911 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$269$117,66413 claims
PfizerEliquis$443$56,87846 claims
Johnson & JohnsonXarelto$815$22,54823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

Other nurse practitioner in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →